WXXWY
New numbers, same uneasy vibe
WuXi Biologics dropped its latest results and guidance, and on paper the update looks pretty solid: 2025 revenue came in at RMB 21.79 billion, net profit hit RMB 4.91 billion, and the company said it landed a record 209 new projects. It also ended the year with a hefty US$23.7 billion order backlog, which is the kind of number that makes you picture a conveyor belt running well into the future.
But the market is acting like it read the fine print twice
Despite the upbeat operating stats, the stock was under pressure — opening flat and then sliding more than 3% intraday. The article points to a rising put-to-call ratio of 1.53, which suggests traders are buying protection like they’re expecting a bumpy road ahead.
The part investors will care about
The real takeaway is the 2026 outlook. WuXi Bio guided for revenue growth of 13% to 17%, which tells you management still sees healthy expansion ahead, even if the market isn’t exactly throwing confetti. When a company posts strong earnings and still gets sold off, that usually means investors are worried about what comes next, not what just happened.
Big picture
This looks less like a business problem and more like a sentiment problem — at least for now. If the order backlog keeps growing and the guidance holds up, today’s dip could look like nervous trading rather than a fundamental panic.